Reaction
Lung Adenocarcinoma Stage Iv reporting signals
As of the last recalculation, Lung Adenocarcinoma Stage Iv appears in 375 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is CRIZOTINIB (PRR 111.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Crizotinib | 24 | 111.9 | 112.1 |
| Pemetrexed | 37 | 106.2 | 106.3 |
| Erlotinib | 15 | 89.5 | 89.6 |
| Gefitinib | 14 | 89.4 | 89.5 |
| Erlotinib Hydrochloride | 19 | 88.7 | 88.9 |
| Pemetrexed Disodium | 44 | 72.5 | 72.6 |
| Dabrafenib | 19 | 52.7 | 52.7 |
| Trametinib | 21 | 51.0 | 51.1 |
| Guselkumab | 18 | 29.3 | 29.3 |
| Fluticasone Furoate And Vilanterol Trifenatate | 18 | 29.1 | 29.1 |
| Osimertinib | 16 | 28.9 | 28.9 |